Jean-Luc M. Lemercier - Jul 7, 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, EMEA, Canada, Latin Amer
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Jul 7, 2022
Transactions value $
$0
Form type
4
Date filed
7/11/2022, 08:04 PM
Previous filing
May 17, 2022
Next filing
Mar 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Award $0 +6.1K +3.75% $0.00 169K Jul 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Award $0 +54.5K $0.00 54.5K Jul 7, 2022 Common Stock 54.5K $98.43 Direct F2
transaction EW Performance Rights Award $0 +7.63K $0.00 7.63K Jul 7, 2022 Common Stock 7.63K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units were granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
F2 These options were granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
F3 Reflects the target number of shares (the Target Award) covered by restricted stock units granted on July 7, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on July 7, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.